Curriculum Vitae
Sabita Roy, Ph.D.

Education
Academic Appointments
Scientific Activities
Grant Support
  Active, Pending, Past
Honors and Awards
Societies and Memberships
Invited Presentations
Other Presentations
Committee and Administrative Service
Bibliography
Peer Reviewed Articles
Book Chapters
Invited Reviews

EDUCATION

1977, B.Sc - Biology
Panjab University, Chandigarh, India  

1981, M.Sc. - Medical Sciences
All India Institute of  Human Physiology, New Delhi, India

1986, Ph.D. - Neurobiology
University of Kansas, Lawrence

Post Doctoral Training

1986-1988, Pharmacology
Department of Pharmacology, University of California San Francisco

1988-1990, Pharmacology
Department of Pharmacology, University of Minnesota, Minneapolis

Top of page

ACADEMIC APPOINTMENTS

July 2006-present, Professor and Director
Division of Infection Inflammation and Vascular Biology
Department of Surgery, University of Minnesota, Minneapolis (UMN)

July 2006-present, Professor
Department of Pharmacology, UMN

July 1999-2006, Associate Professor
Department of Pharmacology, UMN

July 1999-present, Associate Professor
Department of Surgery, UMN

Jan. 1993-June 1999, Assistant Professor
Department of Pharmacology, UMN

Sept. 1992-June 1999, Assistant Professor
Department of Surgery, UMN

Nov. 1989-Aug. 1992, Research Associate
Department of Pharmacology, UMN

Top of page

SCIENTIFIC ACTIVITIES

Director of Graduate Studies (2006-2007)
  Department of Pharmacology

NIH Study Section Member
Full member
  National Institute of Drug Abuse Study Section, NIDA-K: Training and Career
  Development Review Committee study Section (1999-2002)
Full member
  National Institute of Drug Abuse Study Section, NIDA-K: Training and Career
  Development Review Committee study Section (2002-2004)
Ad Hoc Member
  National Institute of Drug Abuse Study Section, NIDA-K: Training and Career
  Development Review Committee study Section (03/05, 03/07, 11/07)
Full member
  National Institutes of Health: NAED Study Section (2004-2008)
Ad Hoc Reviewer
  NIDA Center Grant Committee (March 2005)

Editorial Board
Journal of NeuroImmune Pharmacology

Manuscript Reviewer
Journal of Neuroimmunology - Ad Hoc
Journal of Leucocyte Biology-Ad Hoc
Journal of Immunology-Ad Hoc
Blood –Ad Hoc
International Immunology-Ad Hoc
Clinical Immunology-Ad Hoc
Journal of Cellular Biochemistry
Journal of Pharmacology and Experimental Therapeutics-Ad Hoc
Journal Cellular Immunology-Ad Hoc
Journal of Neurochemistry

Membership in Programs
Co-Director (2006-Present) - PNI Training grant
Councilor (2002-2004) - Society for Neuroimune Pharmacology
Re-elected Councilor (2005-2008)- Society for Neuroimune Pharmacology
Member: American Association of Immunologists
Panel Member: Preparing Future Faculty, University of Minnesota
Reviewing Member: Distinguished Women Scholars Award (DWSA) Review Committee, University of Minnesota

Top of page

GRANT SUPPORT

Active Grants

Grant Number: R01 DA12104
Title: Role of Mu- Opioid receptor in Immune function
Duration: 1999 -2008
Funding Agency: National Institute of Drug Abuse
P.I.: Sabita Roy

Grant Number: 3R01 DA12104-06S1
Title: Role of Mu- Opioid receptor in Immune function
Duration: 2003-2008
Funding Agency: National Institutes of Health.
P.I.: Sabita Roy

Grant Number: R01 DA022935
Title: Morphine, Wound Healing and HIV Proteins
Duration: 2007 -2012
Funding Agency: National Institute of Drug Abuse
P.I.: Sabita Roy

Grant Number: P50 DA011806
Title: Basic Research Center on Molecular & Cell Biology of Drug Abuse
Duration: 1999-2008
Funding Agency: National Institute of Drug Abuse (NIH)
P.I.: Dr. Horace Loh
Program Component 5: Role of Mu-Opioid Receptor in Stress Induced Immunosuppression
P.I.: Sabita Roy

KO2
Funding Agency: National Institute of Drug Abuse (NIDA)
Duration: 2007-2012
Title: Mechanism of Morphine induced immunosuppression
P.I.: Sabita Roy

Instrument Grant
Funding Agency: Minnesota Medical Foundation
Duration: 2005-2007
P.I.: Sabita Roy

Research Grant: F31 NSRA
Funding Agency: National Institute of Drug Abuse
Duration: 2006-2008
Title: Morphine modulates HIf 1 alpha to suppress tumor growth
P.I.: Lisa Koodie
Role: Mentor

Grant Number: T32 DA07097
Title: PharmacoNeuroImmune Training Grant
Duration: 2007-2012
P.I.: Tom Molitor
Co-PI Sabita Roy

Research Grant: R 03
Funding Agency: National Institutes of Health
Duration: 2005-2007
Title: Morphine Induced Defect in S. Pneumonia Defense
P.I.: Jing Hua Wang
Role: Co-PI

Top of page

Pending

Research Grant: R 21
Funding Agency: National Institutes of Health
Duration: 2007-2009
Title: Mu-opioid receptor, Stress, HPA and Addiction
P.I.: Sabita Roy

Research Grant: RO1
Funding Agency: National Institute of Health
Duration: 2007-2012
Title: Stent induced artery wall hypoxia and intimal hyperplasia
P.I.: Steven Santili
Role: Co-Investigator

Top of page

Past Support

Research Grant: F31 NSRA
Funding Agency: National Institute of Drug Abuse
Duration: 2005-2006
Title: Morphine Withdrawal induced Th2 differentiation
P.I.: Jennifer Kelschenbach
Role: Mentor

KO2
Funding Agency: National Institute of Drug Abuse (NIDA)
Duration: 2002-2007
Title: Mechanism of Morphine induced immunosuppression
P.I.: Sabita Roy

Lillehei Scholars program - Grant Revision Award (2002-2003)
Title: Morphine Inhibits Hypoxia induced VEGF: Implications in
Myocardial Infarction
P.I.: Sabita Roy

Grant Number: R01 DA12104
Title: Role of Mu- Opioid receptor in Immune function
Duration: 1999-2003
Funding Agency: National Institutes of Health.
P.I.: Sabita Roy

Grant Number: P50 DA011806
Title: Basic Research Center on Molecular & Cell Biology of Drug Abuse
Duration: 1999-2003
Funding Agency: National Institute of Drug Abuse (NIH)
Program Component 5: Inhibition of Cytokine Gene Expression by Morphine
P.I.: Sabita Roy

First Investigator Research Award (R-29)
Funding Agency: National Institute of Drug Abuse (NIH)
Duration: 1994-1999
Title: Effects of Morphine on Immune Cells.
P.I.: Sabita Roy

Funding Agency: Minnesota Medical Foundation
Title: Mechanism of Morphine Induced Immunosupression
Duration: (1992-1993)
P.I.: Sabita Roy

Individual National Research Service Award (Post-Doctoral)
Title: Immunochemical Characterization of Mu-opioid receptor
Funding Agency: National Institute of Drug Abuse (NIH)
Duration: 1986-1989
P.I.: Sabita Roy

Funding Agency: Minnesota Medical Foundation
Title: Effect of Morphine on Macrophage Colony Formation.
Duration: 1993-1994
P.I.: Sabita Roy

Title: Regulation of Gene Expression Following Sepsis.
Duration: 1998-2001
Funding Agency: Department of Defense
P.I.: Roderick Barke
Co-Investigator: Sabita Roy

Top of page

HONORS AND AWARDS

B.K. Anand Gold Medal for best graduate student in Physiology, All India Institute of Medical Sciences. India (1980)

Individual National Research Service Award (Post-Doctoral), National Institute of Drug Abuse ('86-'89)

First Investigator Research Award (R-29), National Institute of Drug Abuse ('94-'99)

Young Investigator Travel Award, National Institute of Drug Abuse to attend and present research findings at ‘The Brain Immune Axis Meeting’, Palm Beach, Florida (1994)

Young Investigator Travel Award, National Institute of Drug Abuse to attend and present research findings at ‘The Brain Immune Axis Meeting’, San Diego, California ('95)

Outstanding Research Service Award, VAMC, Minneapolis ('96, '97, '98)
Charter Member, (SNIP) Society for Neuroimmunopharmacology ('01-present)
Chairman, Young Investigator Travel Award Committee, SNIP ('02, '04, '05)
Lillehei Scholar Award ('02-'03)
KO2 Award (NIDA) Independent Scientist Career Development Award ('02-'07)
Elected Councilor at Large, SNIP ('02-'05)
Re-Elected Councilor at Large, SNIP ('05-'08)
Steering Committee, PNI Training grant ('03-present)
Co-Director, PNI Training grant ('06-present)
Director of Graduate Studies, Department of Pharmacology ('06-present)
KO2 Award (NIDA) Independent Scientist Career Development Award ('07-'12)
Distinguished Service Award, Society of NeuroImmune Pharmacology (April '07)
Mentor, Young Investigator Grant Writing Seminar, SNIP ('07, '08)
Mentor, Annual “Meet the Mentor Dinner” SNIP ('07, '08)

Top of page

SOCIETIES AND MEMBERSHIPS

Society for Neuroimmunopharmacology
 • Chairman, Young Investigator Travel Award Committee (2002, 2004, 2005)
 • Charter Member (2001-present)
 • Elected Councilor at Large (2002-2005)
 • Re-Elected Councilor (2005-2008)
 • Program Committee (2006)
 • Councilor and Chairman of Communication Committee (2008-2011)

American Association of Immunologists, Invited Member

International Narcotic Research Conference, Member
 • Local Organizing Committee member for 2006 meeting

College on Problems of Drug Dependence, Member

Top of page

INVITED PRESENTATIONS

Invited Lectures

1. “Mechanisms of Morphine-Induced Immunomodulation.” Psychoneuroimmunology Group, Hennepin County Medical Center, Minneapolis, MN (February 1994)

2. “Mechanisms of Morphine-Induced Immunomodulation,” Department of Pharmacology, University of Minnesota  (June 19, 1997)

3. “Mechanisms of Morphine-Induced Immunomodulation,” Department of Infectious Diseases, VA Medical Center, Minneapolis, MN (April 12, 1999)

4. “Role of Mu-Opioid Receptor in Morphine-Induced Immunomodulation,” Clinical Pharmacology and Drug Delivery, Annual Meeting, Acapulco (June 1999)

5. “Role of Mu opioid receptor in T Cell Function,” National Institute of Health-Brain Immune Meeting, NIH, Bethesda, MD (October 9, 1999)

6. “Mu opioid receptor and immunomodulation,” Department of Biology, Seton Hall University, Orange, NJ (October 20, 1999)

7. “Morphine’s Role in Immunomodulation,” Department of Pharmaceutics, School of Pharmacy, University of Minnesota (April 2000)

8. “Role Of Mu Opioid Receptor in Immune Function,” PsychoNeuroImmunology Program University of Minnesota (May 2000)

9. "Morphine Modulates T Cell Differentiation,”Society for Neuroimmune Pharmacology, Emory University (March 2001)

10. “Differentiation of Th1/Th2 Function by Morphine,” PsychoNeuroimmunology Research Society, Madison, WI (May 2002)

11. “Morphine Modulates T Helper Cells to Th2 Effector Cells, “Society for Neuroimmunopharmacology, Clearwater, FL (October 2002)

12. “Role of Mu opioid receptor in Immune Function,” International Narcotic Society Meeting, Helsinki, Finland (July 2003)

13. “Modulation of Immune Function by Morphine,” Lillehei Institute, University of Minnesota (October 2003)

14. “Modulation of T Cell Function by Morphine” Vascular Biology Group, University of Minnesota (September 2004)

15. "Role of Mu opioid Receptor in T Cell Modulation by Morphine, “Society for Neuroimmunopharmacology, Clearwater, FL (April 6, 2005)

16. “Modulation of T Cell Function by Morphine: Implication to susceptibility to infection,” Comparative Biomedical Sciences Seminar Series, St Paul, MN (February 2005)

17. “Modulation of T Cell Function by Morphine: Implication to susceptibility to infection,” Society for Neuroimmunopharmacology, Clearwater, FL (March 2005)

18. “Modulation of T Cell Function by Morphine: Implication to susceptibility to infection,” Long Island Jewish Hospital, Long Island, NY (May 24, 2005)

19. “Modulation of T Cell Function by Morphine: Implication to susceptibility to infection,” University of Nebraska, Omaha, NE (June 17, 2005)

20. “Mechanisms of Morphine-Induced Immunomodulation: Implication to susceptibility to infection,” University of Minnesota, Duluth (January 23, 2006)

21. “Interactions between opiate dependence and neuroendocrine responses to stress,” British Association of Psychopharmacology (July 2006)

22. “Mechanisms of Morphine-Induced Modulation of T cell function: Drexel University Philadelphia, (May 22nd, 2006)

23. Modulation of Innate Immune System by Morphine - Kovalam Symposium on HIV AIDS, Trivandrum, India (November 2006)

25. Mechanism of Opioid Induced Immunosuppression, - Louisiana State University, Shreveport, LA (Oct 3rd 2006)

26. Opioids and immune suppression-HIV/AIDS and Drug Abuse Conference, San Juan Puerto Ricoh, (Dec 2006)

27. “Modulation of Immune Function by Morphine”  Society for Neuroimmunopharmacology, Salt Lake City, UT (Apri 2007)

28. "International Conference on Opportunistic Pathogens in AIDS" January 28-January 31, New Delhi India

29. “Morphine and Sepsis”  Society for Neuroimmunopharmacology, Charleston, S. Carolina (March 2008)

30. Drugs of Abuse and  AIDS" December, Chandigargh, India (2008)

Top of page

OTHER PRESENTATIONS

Oral Presentations selected by Peer review

Surgical Infection Society, Louisville, Kentucky (1995)
Surgical Infection Society (1996)
Surgical Infection Society, Society of University Surgeons, New Orleans (02/99)
Plenary Session (4 of 400 abstracts selected) Society of University Surgeons, Chicago (02/00)

Top of page

COMMITTEE AND ADMINISTRATIVE SERVICE

National

Full Member, National Institute of Drug Abuse (NIDA-K) (1999-2004)
Full member, National Institute of Health-NAED Study Section (2004-2008)
AdHoc Member, National Institute of Drug Abuse (NIDA-K) (2004, 2005)
Ad Hoc member, NIDA Center Grant Committee (2005)

University

VA Medical Center, Subcommittee on Animal Studies (IAACUC) (1998-2004)
VA Medical Center, R & D Committee (2002-2004)
TTRUC, Grant Reviewer (2005)
Director of Graduate Students (2006), Department of Pharmacology

Medical School

VA Medical Center, R&D Committee (University representative) (2004-present)
Graduate Faculty in the Field of Pharmacology, Full Member (1997-present).
Director of Graduate Students (2006, Department of Pharmacology)
Distinguished Women Scholars Award (DWSA) Review Committee member (2007)

Department

Seminar Committee (2004-2005)
Faculty Search Committee (2004-2005)
Promotion and Scholastic Committee (2004-2005)
Graduate Committee (2005-2006)
Director of Graduate Students (2006) Department of Pharmacology

Top of page

BIBLIOGRAPHY

Peer Reviewed Articles

1. Roy S and Nayar U (1980) Retrograde transport of HRP in rat sciatic nerve in control and under-nourished rats. Indian J. Physiol. and Pharmacol. 23: 45-49.

2. Michaelis EK, Chang HH, Roy S, McFaul JA and Zimbrick JD (1983) Ethanol effects on synaptic glutamate receptor function and on membrane lipid organization. Pharmac. Biochem. Behav. 18(suppl.1): 1-6.

3. Chang HH, Michaelis EK and Roy S (1984) Functional Characteristics of L-glutamate, N-Methyl -D-Aspartate and Kainate receptors in isolated brain membranes. Neurochem. Research. 9(7): 903-915.

4. Roy S and Michaelis EK (1984) Antibodies against the bovine brain glutamate binding protein. J. Neurochem. 42: 838-841.

5. Roy S, Galton N and Michaelis EK (1985) Effects of anti-glutamate
-binding-protein antibodies on synaptic membrane ion flux, glutamate transport and release, and L-glutamate binding activities. J. Neurochem. 44: 1809-1815.

6. Michaelis EK, Roy S, Galton N, Cunningham M, LeCluyse E and Michaelis ML (1987) Neurochem. Int. 11: 209-218.

7. Roy S, Lee NM and Loh HH (1986) Mu-opioid receptor is associated with phosphatase activity. Biochem. Biophys, Res. Comm. 140(2): 660-665.

8. Roy S and Loh HH. (1987) Biological activity of Mu-opioid receptor. Neuropharm. 26(7B): 917-921.

9. Roy S, Zhu YX, Lee NM and Loh HH (1988) Different molecular weight forms of opioid receptors revealed by Polyclonal Antibodies. Biochem. Biophys. Res. Comm. 150(1): 237-244.

10. Roy S, Zhu YX, Lee NM and Loh HH (1988) A Monoclonal antibody that inhibits opioid binding to rat brain membranes. Biochem. Biophys. Res. Comm. 154(2): 688-693.

11. Bero L, Roy S and Lee NM (1988) Identification of endogenous opioid receptor components in rat brain using a monoclonal antibody. Molecular Pharm. 34: 614-620.

12. Schofield PR, McFarland KC. Hayflick, Wilcox JN, Cho TM, Roy S, Lee NM, Loh HH and Seeburg PH (1989) Molecular characterization of a new immunoglobulin superfamily protein with potential roles in opioid binding and cell contact. EMBO J. 8(2): 498-495.

13. Roy S, Ramakrishnan S, Loh HH and Lee NM (1991) Chronic Morphine treatment selectively suppresses macrophage colony formation in bone marrow. Eur. J. Pharm. 195: 359-363.

14. Roy S, Lee NM, Ramakrishnan S and Loh HH (1991) 3H-Morphine binding is enhanced by IL-1 stimulated thymocyte proliferation. FEBS Lett.  287: 93-96.

15. Roy S, Loh HH and Lee NM (1991) Dynorphin Blocks Opioid Inhibition of M-CSF Induced Proliferation of Bone Marrow Cells. Eur. J. Pharmacology 202: 355-359.

16. Barke RA, Brady PS, Roy S, Charboneau R, Brady LJ (1992) The possible inhibitory role of the DNA binding protein c-Fos in the regulation of gene expression in sepsis. Surgery 112(2): 412-418.

17. Roy S, Ge BL, Loh LL and Lee NM (1992) Characterization of 3H-Morphine binding to Interleukin-1 activated Thymocytes. J. Pharm. Exp. Ther.  263(2): 451-456. 

18. Roy S, Chapin R, Charboneau R, Brady PS, Brady LJ and Barke RA (1994) The role of programmed cell death (apotosis) in thymic involution following sepsis. Arch. Surgery 129: 1256-1262.

19. Chapin R, Roy S,Charboneau R, Brady PS, Brady LJ and Barke RA (1994) Regulation of the transcription factor C/EBP following peritoneal sepsis. J. Surg. Res. 215: 156-167.

20. Roy S, Chapin R, Charboneau R, Brady PS, Brady LJ and Barke RA (1994) Sepsis induced release of Interleukin-6 may activate the immediate early gene program through a hypothalamic-hypophyseal mechanism. Surgery 116: 141-149. 

21. Roy S, Loh HH and Barke RA (1995) Morphine Induced Supression of Thymocyte Proliferation is Mediated by Inhibition of IL-2 synthesis. Adv. Exp. Med. Biol. 373: 41-48.

22. Wick, MJ, Minnerath, SR, Roy S, Ramakrishnan S, and Loh HH (1995) Expression of alternate forms of brain opioid “orphan” receptor mRNA in activated human peripheral blood lymphocyes and lymphocytic cell lines. Mol. Brain Res. 32: 342-347.

23. Sedqi M, Roy S, Ramakrishnan S, Elde R and Loh HH (1995) Complementary cloning of a m-opioid receptor from rat peritoneal macrophages. Biochem. Biophys. Res. Comm. 208(2): 563-574.

24. Roy S, Charboneau R, Chapin R, Cain K and Barke RA (1995) The possible role of a CNS Dopiminergic Mechanism in Hepatic protein expression following peritoneal sepsis. Arch. Surg. 130: 1209-1216.

25.  Barke RA, Birklid S, Chapin R, Roy S, Brady PS and Brady LJ (1996) The effect of surgical treatment following peritoneal sepsis on hepatic gene expression. J. Surg. Res. 60: 101-106.

26. Wick MJ, Minnerath SR, Roy S, Ramakrishnan S, Loh HH (1996) Differential expression of opioid receptor genes in human lymphoid cell lines and peripheral blood lymphocytes. Neuroimmunology  64: 29-36.

27. Roy S, Sedqi M, Ramakrishnan S, Barke RA and Loh HH (1996) Differential effects of opioids on the proliferation of a macrophage cell line. Cellular Immunology 169-174.

28. Roy S and Loh HH (1996) Effects of Opioids on the Immune System. Neurochemical Research  21(11): 1373-1384.

29. Sedqi, M, Roy S, Mohanraj D, Ramakrishnan S and Loh HH (1996) Activation of rat with Interleukin-1 selectively upregulates the expression of somatostatin receptor subtype-Biochem. Mol. Biol. Inter. 38: 103-11.

30. Sedqi M, Roy S, Ramakrishnan S and Loh HH (1996) Expression cloning of a full length cDNA encoding delta opioid receptor from mouse thymocytes. J. Neuroimmunology 65: 167-170.

31. Roy S, Chapin R, Cain K, Charboneau R, Ramakrishnan S and Barke RA (1997) Morphine inhibits transcriptional regulation of IL-2 synthesis in thymocytes. Cell. Immunol. 179: 1-9.

32. Chandrashekhar Y, Sen S, Roy S, Liu DS and Anand IS (1997) Arginine Vasopressin receptor mRNA levels are reduced in the failing rat mycardium. Am. J. Cardiol.  29: 282.

33. Olson TA, Mohanraj D, Roy S and Ramakrishnan S (1997) Targeting the tumor vasculature-Inhibition of tumor growth by a vascular endothelial growth factor toxin conjugate (1997). Int. J. Cancer 73(6): 865-870.

34. Roy S, Cain K, Chapin R, Charboneau R and Barke RA (1998) Morphine modulates NFkB activation in macrophages. Biochem. Biophysic. Res. Comm. 245: 392-396.

35. Roy S and Loh HH (1998) Mu-receptor knockout mice: the role of Mu-opioid receptor in gastrointestinal transit. Mol. Brain Res. 56: 281-283.

36. Carson L, Roy S, Cain K, Charboneau R and Barke RA (1998) The hypothalamic hypophyseal genotypic response to ovarian carcinoma simulates the response to sepsis. J. Surg.Res. 75(2): 97-102.

37. Roy S, Chapin R, Cain K, Charboneau R and  Barke RA (1998) Morphine accelerates the progression of sepsis. Adv. Exp. Med. Biol. 437: 21-31.

38. Roy S, Barke RA and Loh HH (1998) Mu-receptor knockout mice: the role of Mu-opioid receptor in Immune Functions. Mol. Brain Res.  61(1-2): 190-194.

39. Roy S, Charboneau R and  Barke RA (1999) Morphine synergizes with LPS in an experimental sepsis model. J.Neuroimmunol. 95: 107-114.

40. Roy S, Charboneau R, Cain K, Melnyk DL, Deturris S and Barke RA (1999) Deficiency of the Transcription Factor c-Fos increase LPS induced macrophage IL-12 production.  Surgery 126(2): 239-47.

41. Roy S, Charboneau R., Melnyk DL, Barke R.A (2000) Interleukin 4 regulates macrophage Interleukin 12 protein synthesis through a c-fos mediated mechanism. Surgery 128: 219-24.

42. Roy S, Charboneau R, Barke RA and Loh HH (2001) Role Mu-opioid receptor in immune function. Adv. Exp. Med. Biol. 493: 117-26.

 43. Roy S, Balasubramanian S, Wang JH, Barke RA and Loh HH (2001) Role of Hypothalamic Pituitary Axis in Morphine induced alteration in Thymic Cell distribution using Mu-Opioid Receptor Knockout Mice. J. Neuroimmunology 116(2): 147-55.

44. Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH and Roy S (2001) Morphine modulates lymph node-derived T lymphocyte function: role of caspase-3, -8, and nitric oxide. J. Leukoc. Biol. 70(4): 527-36.

45. Roy S, Balasubramanian S, Sumandeep S, Charboneau R, Wang J, Melnyk D, Beilman GJ, Vatassery R and Barke RA (2001) Morphine directs T cells toward TH2 differentiation. Surgery Aug;130(2):304-9.

46. Balasubramanian S, Ramakrishnan S. Barke RA and Roy S (2001) Morphine modulates hypoxia induced VEGF expression in endothelial cells  J. Mol. Cell. Cardiol., 33(12):2179-2187.

47. Wang JH, Charboneau RG, Barke RA, Loh H.H. and Roy S (2002) The Immunosupressive efffects of chronic Morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor J of Leukoc. Biol. 71: 782-790.

48. Wang JH, Charboneau RG, Barke RA, Loh H.H. and Roy S (2002) Mu opioid Receptor Mediates Restraint Stress Induced immunosuppression. J Immunol, 169: 3630-3636.

49. Roy S, Balasubramanian S, Chandrashekhar Y, Wang JH, Charboneau R and Barke RA (2003) Morphine inhibits VEGF expression in myocardial ischemia. Surgery 134(2): 336-44.

50. Tomassini N, Renaud FL, Roy S and Loh HH (2003) Mu and delta receptors mediate morphine effects on phagocytosis by murine peritoneal macrophages. J. Neuroimmunol. 136(1-2): 9-16.

51. Wang J, Barke RA, Charboneau R, Loh HH, Roy S (2003) Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP dependent pathways. J. Biol. Chem. 278: 37622.

52. Roy S, Wang JH, Sumandeep G, Charboneau RG, Loh HH and Barke RA (2004) Chronic Morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T bet. J. Neuroimmunol. 147: 78-81.

53. Tomassini N, Renaud F, Roy S and Loh HH (2004) Morphine Inhibits Fc-mediated Phagocytosis Through Mu and Delta Opioid Receptors. J. Neuroimmunol. 147(1-2): 131-3.

54. Wang JH, Barke RA, Charboneau R and Roy S (2005) Morphine treatment impairs host innate immune response and increases susceptibility to S. Pneumoniae infection: Role of Galectin-3 and CXC chemokines. J. Immunol. 174: 426-434.

55. Roy S, Guo X, Kelschenbach J, Liu Y and Loh HH (2005) In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J. Neurosci. 25(12):3229-33.

56. Kelschenbach J, Barke RA, Roy S (2005) Morphine withdrawal contributes to Th cell differentiation by biasing cells toward the Th2 lineage. J Immunol. 15;175(4):2655-65.

57. Roy S, Wang JH, Charboneau RG, Loh HH and Barke RA (2005) Chronic Morphine treatment regulates IL-4 synthesis through adenylate cyclase Gai/0 mechanism. J. Immunol. Nov 15;175(10):6361-7.

58. Wang J, Barke RA, Roy S. (2007) Transcriptional and epigenetic regulation of IL-2 gene in activated T cells by morphine. J Biol Chem. 2007 Jan 16; [Epub ahead of print]

59. Hamilton KL, Franklin LM, Roy S, Schrott LM. (2007). Prenatal opiate exposure attenuates LPS-induced fever in adult rats: Role of interleukin-1beta. Brain Res. 2007 Feb 16;1133(1):92-9.

60. Vatassery GT. Quach HT, Smith WE., SantaCruz KS and Roy S (2008) Apolipoprotein E deficiency leads to altered brain uptake of alpha  tocopherol injected into lateral cerebral ventricles. Biochimica et Biophysica Acta  Molecular Basis of Disease Jul;1772(7):797-803. Epub 2007 May 3.

61. Wang JH, Loh HH and Roy S (2008) Differential effects of-endorphin on Mu- and Delta opioid receptor. J. Neuroscience (submitted).

62. Koodie L, Ramakrishnan S and Roy S (2008) Morphine modulates tumor angiogenesis through a HIF alpha dependent pathway. Cancer Res. (submitted). 

63. Kelschenbach J, Barke RA, Roy S (2008) Role of Innate Immunity in Morphine withdrawal. J Immunol. (under revision) 

64. Wang JH, Barke RA, Charboneau R and Roy S (2008) Morphine modulation of alveolar macrophages increases pulmonary s. pneumoniae infection. J Immunology (in press).

65. Kelschenbach J, Ninkovic J, Wang JH, Krishnan A, Charboneau R, Barke RA, Roy S (2008) Morphine withdrawal inhibits inhibits macrophage IL-12 synthesis by modulating the cAMP signaling pathway.  J Immunol. (in press)

66. Kelschenbach J, Barke RA, Roy S (2008) Role of Mu opioid receptor and Corticosterone in Morphine withdrawal mediated Th2 differentiation and suppression of IL-12. JNeuroimmunol. (submitted)

67. Olin MR., Lee B., Roy S and Molitor T (2007) In vivo caspase detection of morphine induced apoptosis. J NeuroImmunepharm (in press)

Top of page

BOOK CHAPTERS

1. Michaelis EK, Roy S, Stormann T and Chang HH (1986) Functional reconstitution of glutamate binding-ion channel activity and immuno-chemical characterization of a glutamate-binding protein from rat brain synaptic membranes. In: Proceedings of the satellite symposium of excitatory amino acids (Roberts PJ, Storm-Matheison Eds.)  Macmillan Press. 

2. Roy S, Loh HH, Zhu YX, Smith AP, Green PG, Bero L and Lee NM (1989) Preparation and Characterization of monoclonal antibodies to purified opioid receptor. In: Neuro. Pharm. A tribute to B.B. Brodie. (Costa E. Ed.) Raven Press, pp. 179-190.

3.  Roy  S and Loh HH (1996) Effects of Opioids on the Immune System. Neurochemical Research 21(11): 1373-1384.

4. Sharp BM, Roy S and Bidlack JM (1998) Evidence for opioid receptors on cells involved in host defense and the immune system. J. Neuroimmunol. 83: 45-56.

5. Roy S, Charboneau R, Barke RA and Loh HH (2002) Role Mu-opioid receptor in immune function. Adv. Exp. Med. Biol. 493: 117-26.

6. Roy S, Wang JH and Barke RA (2005) Morphine, TH1/Th2 Differentiation and Infection. In: Infectious Diseases and Substance Abuse, edited by Herman Friedman et al. Springer, New York, pp. 125-139.

7. Roy S and Loh HH (2006) Role of Mu Opioid Receptors In Stress induced Cytokine modulation. In: Cytokine, Stress and immunity. Springer, New York.

Top of page

INVITED REVIEWS

1. Roy S (2007) Mu Opioid Receptor in Immune Function, Current Reviews in Neurobiology

2. Roy S (2006) Mechanism of Morphine Induced Immunomodulation, Journal of NeuroImmune Pharmacology

Top of page